2021
DOI: 10.1007/s43441-021-00354-0
|View full text |Cite
|
Sign up to set email alerts
|

Quality of FDM 3D Printed Medicines for Pediatrics: Considerations for Formulation Development, Filament Extrusion, Printing Process and Printer Design

Abstract: Abstract3d printing is capable of providing dose individualization for pediatric medicines and translating the precision medicine approach into practical application. In pediatrics, dose individualization and preparation of small dosage forms is a requirement for successful therapy, which is frequently not possible due to the lack of suitable dosage forms. For precision medicine, individual characteristics of patients are considered for the selection of the best possible API in the most suitable dose with the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
31
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
2
1

Relationship

2
8

Authors

Journals

citations
Cited by 48 publications
(32 citation statements)
references
References 117 publications
1
31
0
Order By: Relevance
“…Cost-effectiveness is imperative to successfully implement 3D-printed drug products, as it enhances patient accessibility. Furthermore, regulatory guidelines and non-destructive quality control requirements are yet to be established for 3D-printed drug products, but are needed to ensure user-safety, legal protection and waste-reduction [39,78,79]. The regulatory viewpoint might depend on the starting point of the 3D printing process.…”
Section: Discussionmentioning
confidence: 99%
“…Cost-effectiveness is imperative to successfully implement 3D-printed drug products, as it enhances patient accessibility. Furthermore, regulatory guidelines and non-destructive quality control requirements are yet to be established for 3D-printed drug products, but are needed to ensure user-safety, legal protection and waste-reduction [39,78,79]. The regulatory viewpoint might depend on the starting point of the 3D printing process.…”
Section: Discussionmentioning
confidence: 99%
“…There has been a global recognition for the need to improve access to patient-appropriate formulations for paediatrics. While there has been a lot of research that covers the technical challenge of producing DFs using 3DP and its quality control [ 36 , 37 , 38 ], the acceptability of the 3D printed DFs requires investigation. The study also highlights the potential of CYP themselves as co-designers of personalised DFs that could be produced by 3DP to meet their own needs of acceptable and age-appropriate medicines.…”
Section: Discussionmentioning
confidence: 99%
“…The desired filament diameter was achieved using a belt hauled-off unit of a winder (Brabender, Duisburg, Germany) with a belt speed of 0.8 m/min, and the filament was pulled through a roll-system with four 360° air flow ring nozzles (Super Air Wipe, Exair, Cincinnati, OH, USA) for active cooling of the melt. With a laser-based diameter measurement module (Laser 2025 T, Sikora, Bremen, Germany), we continuously measured and logged the filament diameter during the process with a readout rate of 1 Hz to ensure diameter homogeneity [ 33 ] of PVA-P and EVA-LD-BZ filaments. The screw speed was set to 20 rpm and powder feed rate was set to 2 g/min.…”
Section: Methodsmentioning
confidence: 99%